To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Systems-level immunomonitoring in children with solid tumors to enable precision medicine
Clinical Pediatrics Unit, Department of Women's and Children's Health, Karolinska Institutet, 17165 Stockholm, Sweden.
Clinical Pediatrics Unit, Department of Women's and Children's Health, Karolinska Institutet, 17165 Stockholm, Sweden.
Clinical Pediatrics Unit, Department of Women's and Children's Health, Karolinska Institutet, 17165 Stockholm, Sweden.
Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, 17177 Stockholm, Sweden.
Show others and affiliations
2025 (English)In: Cell, ISSN 0092-8674, E-ISSN 1097-4172, Vol. 188, no 5, p. 1425-1440.e11Article in journal (Refereed) Published
Abstract [en]

Cancer is the leading cause of death from disease in children. Survival depends not only on surgery, cytostatic drugs, and radiation but also on systemic immune responses. Factors influencing these immune responses in children of different ages and tumor types are unknown. Novel immunotherapies can enhance anti-tumor immune responses, but few children have benefited, and markers of effective responses are lacking. Here, we present a systems-level analysis of immune responses in 191 children within a population-based cohort with diverse tumors and reveal that age and tumor type shape immune responses differently. Systemic inflammation and cytotoxic T cell responses correlate with tumor mutation rates and immune cell infiltration. Clonally expanded T cell responses are rarely detected in blood or tumors at diagnosis but are sometimes elicited during treatment. Expanded T cells are similarly regulated in children and adults with more immunogenic cancers. This research aims to facilitate the development of precision immunotherapies for children with cancer.

Place, publisher, year, edition, pages
Cell Press, 2025. Vol. 188, no 5, p. 1425-1440.e11
Keywords [en]
Wilms tumor, cancer immunotherapy, human immunology, immune development, immunotherapy, neuroblastoma, oncology, pediatric, systems immunology
National Category
Cancer and Oncology Immunology
Identifiers
URN: urn:nbn:se:oru:diva-118844DOI: 10.1016/j.cell.2024.12.014ISI: 001444731700001PubMedID: 39837329Scopus ID: 2-s2.0-85217255449OAI: oai:DiVA.org:oru-118844DiVA, id: diva2:1931543
Funder
Swedish Childhood Cancer Foundation, PR2022-0114Swedish Childhood Cancer Foundation, PR2019-0070Swedish Childhood Cancer Foundation, PR2017-0103Swedish Childhood Cancer Foundation, PR2020-0133Swedish Childhood Cancer Foundation, TJ2016-0058Swedish Childhood Cancer Foundation, TJ2019-0111Swedish Childhood Cancer Foundation, KF2023-0004Swedish Research Council, 2019-01495Swedish Research Council, 2020-06190Swedish Research Council, 2020-02889Swedish Research Council, 2021-06529Swedish Research Council, 2021-05450Swedish Research Council, 2022-01567Swedish Cancer Society, 201175PjFSwedish Cancer Society, CAN 2015/587Swedish Cancer Society, CAN 2018/764Karolinska Institute, 2018-02229Knut and Alice Wallenberg Foundation, KAW2023-0344Knut and Alice Wallenberg Foundation, 2019.0191Swedish Society of Medicine, CG-22-0148-H-02
Note

Funding Agencies:

This work was funded by the Swedish Childhood Cancer Fund (PR2022-0114, PR2019-0070, and PR2017-0103 to P.B., PR2020-0133, TJ2016-0058, and TJ2019-0111 to P.K.; and KF2023-0004 to L.L.), Swedish Research Council (2019-01495, 2020-06190, 2020-02889, 2021-06529, 2021-05450, and 2022-01567 to P.B.), the Swedish Cancer Society (201175PjF, CAN 2015/587, and CAN 2018/764 to P.B.), Karolinska Institutet (2018-02229), Göran Gustafsson Foundation (GG2020-0040), Knut & Alice Wallenberg Foundation (KAW2023-0344 and 2019.0191), and the Swedish Society of Medical Research (CG-22-0148-H-02). 

Available from: 2025-01-27 Created: 2025-01-27 Last updated: 2025-03-24Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Repsilber, Dirk

Search in DiVA

By author/editor
Repsilber, Dirk
By organisation
School of Medical Sciences
In the same journal
Cell
Cancer and OncologyImmunology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 62 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf